---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-107115"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2026-09-11T21:00:52+00:00"
generated_at: "2026-09-11T21:02:04.270211+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TransCode CFO Fitzgerald resigns; severance up to $1.25M, interim CFO Tattory appointed

## Summary
- Thomas A. Fitzgerald resigned as CFO, principal financial and accounting officer, and director effective Sept 9, 2026; no disagreement cited.
- Separation agreement includes $1,250,000 severance: $416,666.67 lump sum, $416,666.67 monthly over 12 months, $416,666.67 contingent on funding.
- Third payment accelerates 50% at $5M Qualified Funding, full at $10M; vesting of all outstanding equity awards accelerated, exercise period extended.
- New option granted for 185,000 shares at closing price on Sept 9, 2026, vesting monthly over 12 months with funding-based acceleration.
- John Tattory, 61, appointed interim CFO effective Sept 9, 2026, via Stout Risius Ross; has prior CFO roles at Windtree and Cerapedics.

## SEC filing metadata
- accession: 0001104659-26-107115
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2026-09-11T21:00:52+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465926107115/0001104659-26-107115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465926107115/tm2625146d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-107115
- JSON: https://secwatch.observer/filing/0001104659-26-107115.json
- Plain text: https://secwatch.observer/filing/0001104659-26-107115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.